What are the current management guidelines for diabetic ketoacidosis (DKA) and septic shock, including treatment of hypoxic‑ischemic encephalopathy (HIE) and disseminated intravascular coagulation (DIC)?

Management of DKA and Septic Shock with HIE and DIC

Diabetic Ketoacidosis (DKA) Management

For critically ill DKA patients, initiate continuous intravenous regular insulin at 0.1 units/kg/h only after fluid resuscitation and potassium correction (>3.3 mEq/L), then reduce to 0.05 units/kg/h when glucose falls below 14 mmol/L (252 mg/dL) to prevent hypoglycemia. 1

Initial Resuscitation and Fluid Management

• Begin with isotonic crystalloids at minimum 30 mL/kg for volume restoration, though balanced solutions may achieve faster DKA resolution than normal saline 2
• Restore circulatory volume and tissue perfusion as the primary goal before insulin therapy 1
• Monitor for cerebral edema risk factors, particularly with rapid overcorrection of hyperglycemia—avoid glucose reduction >90 mg/dL/h 2

Insulin Therapy Protocol

• Standard approach: continuous IV regular insulin after potassium ≥3.3 mEq/L and adequate fluid status 1
• British protocol alternative: add subcutaneous glargine insulin alongside IV insulin for faster DKA resolution and shorter hospital stays 2
• Transition to subcutaneous insulin requires basal insulin administration 2-4 hours before stopping IV insulin to prevent rebound hyperglycemia and ketoacidosis recurrence 1
• For mild-moderate DKA: subcutaneous rapid-acting analogs combined with aggressive fluid management are equally effective as IV insulin 1

Electrolyte Management

• Potassium: Monitor closely and replace aggressively—DKA causes total body potassium depletion despite normal/elevated initial levels 2
• Phosphate and magnesium: Check and correct deficiencies regularly throughout treatment 2
• Bicarbonate: Generally NOT recommended—no benefit in acidosis resolution and increases risks of hypokalemia, worsening ketosis, and cerebral edema 1, 2
  • Exception: Consider IV bicarbonate only if pH <6.9, or pH <7.2 with bicarbonate <10 mEq/L pre-intubation to prevent hemodynamic collapse 2

Critical Care Considerations

• Early oral nutrition reduces ICU and hospital length of stay 2
• For respiratory failure: intubate with mechanical ventilation—avoid BiPAP due to aspiration risk 2
• Treat underlying precipitants (sepsis, MI, stroke) concurrently 1

---

Septic Shock Management

Initiate aggressive fluid resuscitation with crystalloids (minimum 30 mL/kg) immediately, followed by norepinephrine as first-line vasopressor targeting MAP ≥65 mmHg, and implement source control within 12 hours of diagnosis. 1

Fluid Resuscitation

• Crystalloids are the initial fluid of choice (strong recommendation) 1
• Either balanced crystalloids or normal saline acceptable 1
• Add albumin when substantial crystalloid volumes are required 1
• Avoid hydroxyethyl starches (strong recommendation against use) 1
• Continue fluid challenge technique as long as hemodynamic improvement occurs (dynamic or static variables) 1

Vasopressor Management

• Norepinephrine is the first-choice vasopressor (strong recommendation) 1
• Target MAP of 65 mmHg initially 1
• Second-line options when additional agent needed:
  • Add vasopressin 0.03 units/min to raise MAP or decrease norepinephrine dose 1
  • Add epinephrine if norepinephrine insufficient 1
• Dopamine only for highly selected patients (low tachyarrhythmia risk, bradycardia) 1
• Do NOT use low-dose dopamine for renal protection (strong recommendation against) 1
• Phenylephrine reserved only for: norepinephrine-induced arrhythmias, high cardiac output with persistent hypotension, or salvage therapy 1
• Place arterial catheter as soon as practical for all patients requiring vasopressors 1

Source Control

• Identify and implement source control intervention as rapidly as possible, ideally within 12 hours of diagnosis 1
• Use least physiologically invasive intervention (percutaneous over surgical drainage when feasible) 1
• Remove intravascular access devices promptly if suspected source after establishing alternative access 1
• Exception: delay intervention for infected peripancreatic necrosis until viable/nonviable tissue demarcation occurs 1

Antimicrobial Therapy

• Daily assessment for de-escalation of antimicrobials 1
• Procalcitonin levels can support shortening antimicrobial duration and discontinuation in patients with limited infection evidence 1

---

Disseminated Intravascular Coagulation (DIC) in Sepsis

Treat the underlying sepsis aggressively as the primary DIC therapy, and consider antithrombin or recombinant thrombomodulin as adjunctive anticoagulation in sepsis-associated DIC with documented coagulopathy. 3

Diagnosis and Monitoring

• Use sepsis-induced coagulopathy (SIC) criteria for early detection: requires only platelet count, PT-INR, and SOFA score 4, 5
• SIC score identifies compensated-phase coagulopathy before overt DIC develops 4
• The 2025 ISTH criteria recognize phase-based classification: Pre-DIC, early-phase DIC, and overt DIC 5
• Overt DIC scoring includes: platelet count, PT-INR, fibrinogen, and D-dimer (>3× upper limit = 2 points; >7× = 3 points) 5
• Distinguish DIC from thrombotic microangiopathy and heparin-induced thrombocytopenia 6

Pathophysiology

• Sepsis-associated DIC involves systemic coagulation activation, suppressed fibrinolysis, and thromboinflammation with activated leukocytes, platelets, and endothelial cells 4, 7
• Results in microvascular thrombosis (thrombotic phenotype) and/or consumption coagulopathy with bleeding (hemorrhagic phenotype) 5
• Damage-associated molecular patterns, neutrophil extracellular traps, extracellular vesicles, and glycocalyx damage contribute to pathogenesis 6

Treatment Approach

• Infection control is crucial and the foundation of DIC management 6, 4, 7
• Antithrombin administration recommended (GRADE 1B) for sepsis-associated DIC 3
• Recombinant thrombomodulin recommended (GRADE 1B) for sepsis-associated DIC 3
• Heparin and serine protease inhibitors lack clear evidence for recommendation 3
• Combination therapy and optimal administration order for antithrombin and thrombomodulin remain research questions 3

Clinical Pitfalls

• Previous clinical trials failed because they included non-coagulopathic patients—screen and monitor using SIC scoring system 4
• DIC is not merely end-stage consumptive coagulopathy but includes early compensated stages requiring intervention 4
• Anticoagulant therapy efficacy must be proven in appropriately selected coagulopathic patients 4

---

Hypoxic-Ischemic Encephalopathy (HIE) Considerations

While the provided evidence does not contain specific HIE guidelines, when managing DKA or septic shock patients with concurrent HIE:

• Avoid rapid glucose correction in DKA to prevent cerebral edema—monitor neurological status closely 2
• Maintain adequate cerebral perfusion pressure with MAP targets in septic shock 1
• Optimize oxygen delivery and avoid hypotension that could worsen cerebral ischemia through aggressive fluid resuscitation and appropriate vasopressor use 1